OrbiMed

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

TriSalus Life Sciences, based in Westminster, Colorado, focuses on developing innovative drug delivery technologies and immune-oncology therapeutics aimed at improving treatment outcomes for challenging cancers, particularly liver and pancreatic cancer. Founded in 2009, the company specializes in precision infusion systems designed for interventional radiology. Its product offerings include Pressure Enabled Drug Delivery (PEDD) systems, which utilize a unique expandable tip catheter to deliver embolic agents while minimizing damage to healthy tissues. The Surefire infusion systems, including various models for lobar, segmental, and super-selective infusions, aim to enhance tumor uptake through controlled pressure and blood flow management. Additionally, TriSalus is advancing an investigational therapy, nelitolimod, which has shown promise in enhancing immune response against liver tumors. The company continues to innovate with devices like the TriNav, which employs SmartValve technology to optimize drug delivery.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing innovative small molecule therapies to enhance patient outcomes. Established in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a unique discovery process that leverages clinically validated biological targets alongside advanced chemistry. This methodology aims to overcome the limitations of current therapies by creating potentially first-in-class treatments that address critical challenges such as tolerability, combinability, resistance, and disease progression, particularly in cases involving brain metastases. Enliven's product pipeline includes ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and act against various HER2 variants.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing innovative small molecule therapies to enhance patient outcomes. Established in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a unique discovery process that leverages clinically validated biological targets alongside advanced chemistry. This methodology aims to overcome the limitations of current therapies by creating potentially first-in-class treatments that address critical challenges such as tolerability, combinability, resistance, and disease progression, particularly in cases involving brain metastases. Enliven's product pipeline includes ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and act against various HER2 variants.

Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.

Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.

Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.

Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.